KRAS and familial pancreatic carcinoma: In the mouse xenograft model of pancreatic cancer, salirasib and gemcitabine inhibited tumor growth by displacing KRAS from the membrane and influenced the reduction of phosphorylation of MAPK and AKT [192,193].